Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$53.30

-0.1401 (-0.26%)

14:07
04/21/17
04/21
14:07
04/21/17
14:07

Bristol-Myers receives 'positive' CHMP opinion on Opdivo approval

Bristol-Myers Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of Opdivo for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy. The CHMP recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union. Opdivo is the first and only PD-1 immune checkpoint inhibitor for the treatment of patients with previously treated mUC to receive a positive CHMP opinion. Opdivo is already approved by the EC for six indications in four distinct tumor types. "We view the CHMP recommendation of Opdivo for previously treated locally advanced or metastatic urothelial carcinoma as an important milestone for the patients. Bristol-Myers Squibb looks forward to collaborating with the European Commission as it considers this potential new indication for Opdivo," said Murdo Gordon, executive vice president and chief commercial officer, Bristol-Myers Squibb.

  • 27

    Apr

  • 02

    May

  • 03

    May

  • 06

    Jun

BMY Bristol-Myers
$53.30

-0.1401 (-0.26%)

03/08/17
PIPR
03/08/17
NO CHANGE
Target $60
PIPR
Neutral
Piper views near-term takeout of Bristol-Myers as unlikely
In a research note titled "Lung Data to Define Value....Not M&A Talk," Piper Jaffray analyst Richard Purkiss contends that news reports suggesting Bristol-Myers (BMY) is a takeover target are "wide of the mark." Industry buyers are unlikely to show interest ahead of the immuno-oncology data readouts in the next 12 months, Purkiss tells investors. He believes the key value-defining events for Bristol over the next year are the four large I/O Combo studies set to read out from mid-2017: AstraZeneca's (AZN) MYSTIC, Merck's (MRK) KN-189, Roche's (RHHBY) IMpower 150 and the company's own CheckMate-227. Ahead of these data, it is virtually impossible to assign a stable fair value to Bristol's I/O franchise, Purkiss argues. He believes investors seeking to benefit from industry consolidation in the near-term should own small- or mid-cap oncology companies. The analyst has a Neutral rating on Bristol with a $60 price target. The stock closed yesterday down 64c to $56.33.
04/03/17
LEER
04/03/17
NO CHANGE
Target $141
LEER
Outperform
Incyte price target raised to $141 from $130 at Leerink
Leerink analyst Michael Schmidt raised his price target for Incyte (INCY) to $141 from $130 as he sees epacadostat better positioned in the emerging IO combination landscape. The analyst notes that the company and Bristol-Myers (BMY) have announced that both companies will advance the combination of Opdivo and epacadostat into several registration trials in 2017. He reiterates an Outperform rating on Incyte's shares.
04/03/17
JPMS
04/03/17
NO CHANGE
JPMS
Overweight
Incyte trial news 'another clear positive,' says JPMorgan
JPMorgan analyst Cory Kasimov views the announcement of epacadostat and nivolumab combo moving into Phase 3 studies in first-line non-small cell lung cancer as well as first-line head and neck cancer in 2017 as "another clear positive" for Incyte (INCY). The stock in early trading is up 5% to $140.73. The news expands the breadth of the epacadostat combinations beyond just Merck (MRK) and could ease fears that Bristol-Myers (BMY) is only focused on its internal molecule, Kasimov tells investors in a research note. The analyst continues to be encouraged by Incyte's progress in immuno-oncology and keeps an Overweight rating on the shares.
04/04/17
RBCM
04/04/17
NO CHANGE
RBCM
Incyte price target raised to $157 from $138 at RBC Capital
RBC Capital analyst Simos Simeonidis raised his price target on Incyte (INCY) after Incyte and Bristol-Myers (BMY) announced that they would conduct Phase III trials of the combination of Incyte's epacadostat and Bristol-Myers' Opdivo in 1L lung and head-and-neck cancer. The analyst notes that Merck last week made a similar announcement regarding the use of epacadostat and Merck's Keutruda in additional Phase III trials. Simeonidis keeps an Outperform rating on Incyte.

TODAY'S FREE FLY STORIES

PYPL

PayPal

$44.41

-0.3 (-0.67%)

09:06
04/27/17
04/27
09:06
04/27/17
09:06
Recommendations
PayPal analyst commentary  »

PayPal margins have…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 20

    Jun

  • 21

    Jun

  • 22

    Jun

  • 22

    Jun

NOVN

Novan

$5.45

0.06 (1.11%)

09:06
04/27/17
04/27
09:06
04/27/17
09:06
Hot Stocks
Novan presents preclinical data from inflammatory skin diseases program »

Novan announced that data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAZZ

Jazz Pharmaceuticals

$157.75

2.85 (1.84%)

09:06
04/27/17
04/27
09:06
04/27/17
09:06
Recommendations
Jazz Pharmaceuticals analyst commentary  »

Jazz Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

HTM

U.S. Geothermal

$4.17

0.04 (0.97%)

09:05
04/27/17
04/27
09:05
04/27/17
09:05
Hot Stocks
U.S. Geothermal provides update on Raft River expansion program »

U.S. Geothermal provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STX

Seagate

$42.01

-8.5 (-16.83%)

09:05
04/27/17
04/27
09:05
04/27/17
09:05
Recommendations
Seagate analyst commentary  »

Seagate selloff following…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jun

09:05
04/27/17
04/27
09:05
04/27/17
09:05
General news
U.S. durable goods orders rose 0.7% in March »

U.S. durable goods orders…

ORI

Old Republic

$20.22

0.15 (0.75%)

09:04
04/27/17
04/27
09:04
04/27/17
09:04
Earnings
Old Republic reports Q1 EPS 39c, consensus 31c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$11.60

0.12 (1.05%)

09:04
04/27/17
04/27
09:04
04/27/17
09:04
Hot Stocks
Ford says 'fit' for any future downturn in North America »

Comments taken from the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

UPS

UPS

$107.62

0.26 (0.24%)

09:04
04/27/17
04/27
09:04
04/27/17
09:04
Hot Stocks
Breaking Hot Stocks news story on UPS »

UPS says Q1 pricing in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 04

    May

  • 16

    May

  • 17

    May

  • 18

    May

  • 19

    May

  • 31

    May

ANTM

Anthem

$179.03

6.57 (3.81%)

, CVS

CVS Health

$82.00

-0.17 (-0.21%)

09:03
04/27/17
04/27
09:03
04/27/17
09:03
Recommendations
Anthem, CVS Health, Express Scripts analyst commentary  »

Anthem price target…

ANTM

Anthem

$179.03

6.57 (3.81%)

CVS

CVS Health

$82.00

-0.17 (-0.21%)

ESRX

Express Scripts

$61.28

1.27 (2.12%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 10

    May

  • 18

    May

  • 06

    Jun

CBS

CBS

$66.91

0.5 (0.75%)

09:03
04/27/17
04/27
09:03
04/27/17
09:03
Recommendations
CBS analyst commentary  »

CBS valuation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 04

    May

  • 08

    May

  • 15

    Jun

GRUB

GrubHub

$35.02

0.24 (0.69%)

09:03
04/27/17
04/27
09:03
04/27/17
09:03
Earnings
GrubHub sees FY17 revenue $632M-$662M, consensus $644.39M »

Sees FY17 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 11

    May

  • 24

    May

  • 25

    May

BANC

Banc of California

$22.45

-0.15 (-0.66%)

09:03
04/27/17
04/27
09:03
04/27/17
09:03
Hot Stocks
Banc of California names Doug Bowers as CEO, effective May 8 »

Banc of California…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

ORRF

Orrstown Financial

$21.95

-0.45 (-2.01%)

09:03
04/27/17
04/27
09:03
04/27/17
09:03
Earnings
Orrstown Financial reports Q1 EPS 24c, consensus 20c »

Net interest income…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

GRUB

GrubHub

$35.02

0.24 (0.69%)

09:02
04/27/17
04/27
09:02
04/27/17
09:02
Earnings
GrubHub sees Q2 revenue $153M-$161M, consensus $157.95M »

Sees Q2 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 11

    May

  • 24

    May

  • 25

    May

GRUB

GrubHub

$35.02

0.24 (0.69%)

09:01
04/27/17
04/27
09:01
04/27/17
09:01
Earnings
GrubHub reports Q1 non-GAAP EPS 29c, consensus 24c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 11

    May

  • 24

    May

  • 25

    May

DISCA

Discovery

$29.39

0.1 (0.34%)

09:00
04/27/17
04/27
09:00
04/27/17
09:00
Periodicals
Discovery Asia partners with VS Media, Tabilabo, Variety says »

Discovery Networks Asia…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 08

    May

  • 18

    May

  • 31

    May

CNMD

CONMED

$48.13

0.93 (1.97%)

09:00
04/27/17
04/27
09:00
04/27/17
09:00
Recommendations
CONMED analyst commentary  »

CONMED price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 24

    May

UA

Under Armour

$18.14

0.17 (0.95%)

, UAA

Under Armour

$19.71

0.18 (0.92%)

09:00
04/27/17
04/27
09:00
04/27/17
09:00
Hot Stocks
Under Armour CFO sees Q4 to be strongest comparison of 2017 'by far' »

Under Armour CFO David…

UA

Under Armour

$18.14

0.17 (0.95%)

UAA

Under Armour

$19.71

0.18 (0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

09:00
04/27/17
04/27
09:00
04/27/17
09:00
General news
U.S. Advance trade deficit in goods widened slightly to -$64.8 B »

U.S. Advance trade…

SNCR

Synchronoss

$24.62

-0.02 (-0.08%)

09:00
04/27/17
04/27
09:00
04/27/17
09:00
Hot Stocks
Breaking Hot Stocks news story on Synchronoss »

Synchronoss trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

BGSF

BG Staffing

$15.15

-0.27 (-1.75%)

08:58
04/27/17
04/27
08:58
04/27/17
08:58
Earnings
BG Staffing reports Q1 EPS 15c, consensus 12c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

TMO

Thermo Fisher

$168.01

9.2 (5.79%)

08:58
04/27/17
04/27
08:58
04/27/17
08:58
Recommendations
Thermo Fisher analyst commentary  »

Thermo Fisher price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    May

  • 06

    Jun

SNBC

Sun Bancorp

$25.70

-0.05 (-0.19%)

08:57
04/27/17
04/27
08:57
04/27/17
08:57
Earnings
Sun Bancorp reports Q1 EPS 7c, consensus 8c »

Reports Q1 NII $14.78M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 15

    May

UPS

UPS

$107.62

0.26 (0.24%)

08:57
04/27/17
04/27
08:57
04/27/17
08:57
Hot Stocks
UPS says sees margin improvement in 2017 »

Expects revenue to grow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 04

    May

  • 16

    May

  • 17

    May

  • 18

    May

  • 19

    May

  • 31

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.